Compare Abeona Therapeutics Inc (ABEO) vs Datadog Inc (DDOG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Datadog Inc — how do they compare? Abeona Therapeutics Inc trades at $6.77 (market cap $373.32M), while Datadog Inc trades at $258.7 (market cap $91.41B). The key difference: Datadog Inc is far larger — about 244.9× Abeona Therapeutics Inc's market cap. Which is the better fit depends on your goals.
| ABEO | DDOG | |
|---|---|---|
Market Cap | $373.32M | $91.41B |
Sector | Health | Technology |
52-Week High | $7.23 | $277.49 |
52-Week Low | $4.17 | $102.62 |
Enterprise Value | $228.22M | $87.94B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Datadog (DDOG) trades at $256.81, down 1.36% over the past day but maintains a bullish technical outlook with strong moving average signals. The company reported revenue of $3.43B in 2025 with consistent earnings beats, though net income margin compressed to 3.69%. Recent acquisition of Adaptive ML aims to bolster AI research capabilities, while analyst sentiment remains overwhelmingly positive with 83% buy ratings.
DDOG presents growth potential through cloud infrastructure demand and AI integration, but faces risks from high valuation multiples (P/E 654.79) and negative cash flow trends. Competition in observability software and execution challenges could pressure margins, though institutional support provides stability. The stock's trajectory hinges on sustaining revenue growth while improving profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Datadog Inc
Datadog is a cloud-native company that focuses on analyzing machine data. The firm's product portfolio, delivered as software-as-a-service, allows a client to monitor and analyze its entire IT infrastructure. Datadog's platform can ingest and analyze large amounts of machine-generated data in real time, allowing clients to utilize it for a variety of different applications throughout their businesses.
Read more on DDOG →
